CAM
APLS

Cormorant Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Cormorant Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-400,000
Closed -$23.5M – 51
2024
Q1 		$23.5M Sell
400,000
-225,000
-36% -$14.3M 1.03% 31
2023
Q4 		$37.4M Sell
625,000
-1,375,000
-69% -$69.8M 1.79% 16
2023
Q3 		$76.1M Buy
2,000,000
+690,000
+53% +$30.3M 4.44% 5
2023
Q2 		$119M Sell
1,310,000
-50,000
-4% -$4.31M 6.69% 3
2023
Q1 		$89.7M Sell
1,360,000
-216,872
-14% -$12.5M 5.91% 4
2022
Q4 		$81.5M Buy
1,576,872
+98,872
+7% +$5.24M 5.46% 2
2022
Q3 		$101M Buy
1,478,000
+528,000
+56% +$31.2M 7.06% 2
2022
Q2 		$43M Sell
950,000
-175,000
-16% -$7.98M 3.25% 5
2022
Q1 		$57.2M Buy
1,125,000
+500,000
+80% +$22.1M 4.39% 6
2021
Q4 		$29.6M Sell
625,000
-300,000
-32% -$11.8M 1.76% 18
2021
Q3 		$30.5M Buy
925,000
+75,000
+9% +$4.21M 1.24% 25
2021
Q2 		$53.7M Sell
850,000
-1,016,108
-54% -$52.4M 1.82% 15
2021
Q1 		$80.1M Hold
1,866,108
– – 1.78% 13
2020
Q4 		$107M Hold
1,866,108
– – 2.54% 9
2020
Q3 		$56.3M Sell
1,866,108
-200,000
-10% -$5.98M 2.16% 12
2020
Q2 		$67.5M Sell
2,066,108
-200,000
-9% -$6.42M 2.57% 11
2020
Q1 		$60.7M Sell
2,266,108
-433,892
-16% -$15.4M 2.82% 11
2019
Q4 		$82.7M Sell
2,700,000
-276,000
-9% -$7.64M 3.3% 8
2019
Q3 		$71.7M Buy
2,976,000
+9,892
+0.3% +$272K 4.36% 4
2019
Q2 		$75.2M Sell
2,966,108
-633,892
-18% -$12.9M 4.32% 5
2019
Q1 		$70.2M Sell
3,600,000
-902,498
-20% -$14.2M 4.74% 5
2018
Q4 		$59.4M Buy
4,502,498
+330,000
+8% +$5.06M 4.82% 5
2018
Q3 		$74.2M Sell
4,172,498
-140,000
-3% -$2.59M 4.82% 6
2018
Q2 		$94.9M Buy
4,312,498
+224,269
+5% +$5.15M 7.02% 1
2018
Q1 		$90.4M Buy
4,088,229
+319,472
+8% +$6.28M 6.74% 4
2017
Q4 		$81.8M Buy
+3,768,757
New +$55.5M 8.56% 3

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cormorant Asset Management's APLS Position: Q2 2024 in Review

Cormorant Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 400,000 shares — an estimated $23.5M sold.

Cormorant Asset Management first reported a position in APLS in Q4 2017 and held it in 26 quarters. The position peaked at $119M in Q2 2023. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Cormorant Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 400,000 Apellis Pharmaceuticals shares in Q2 2024, an estimated $23.5M.
  • Cormorant Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 26 quarters.
  • Cormorant Asset Management's Apellis Pharmaceuticals position peaked at $119M in Q2 2023.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.